{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:22:48Z","timestamp":1790079768750,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vaccine.2024.01.045","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:11:51Z","timestamp":1706800311000},"page":"1799-1811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-9949","authenticated-orcid":false,"given":"Linda","family":"Sch\u00f6nborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-5614","authenticated-orcid":false,"given":"Sue","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien Mun Yee","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-689X","authenticated-orcid":false,"given":"Menaka","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalha Haliru","family":"Gwarzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-2035","authenticated-orcid":false,"given":"Jim","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7689","authenticated-orcid":false,"given":"Flor M.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-959X","authenticated-orcid":false,"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.045_b0005","unstructured":"Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS). 2021. Last accessed 23 October 2023; Available from: https:\/\/brightoncollaboration.us\/thrombosis-with-thrombocytopenia-syndrome-interim\/."},{"key":"10.1016\/j.vaccine.2024.01.045_b0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.045_b0015","series-title":"Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology)","article-title":"The Brighton Collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization","author":"Kohl","year":"2005"},{"key":"10.1016\/j.vaccine.2024.01.045_b0020","unstructured":"Oxford University. Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine. 2020. Last accessed 27 November 2023; Available from: https:\/\/www.ox.ac.uk\/news\/2020-12-30-oxford-university-welcomes-uk-regulatory-emergency-use-authorisation-coronavirus."},{"key":"10.1016\/j.vaccine.2024.01.045_b0025","unstructured":"European Medicines Agency. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU. 2021. Last accessed 27 November 2023; Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu."},{"key":"10.1016\/j.vaccine.2024.01.045_b0030","unstructured":"Australian Government Department of Health and Aged Care Therapeutics Goods Administration. COVID-19 Vaccine AstraZeneca. 2021. Last accessed 27 November 2023; Available from: https:\/\/www.tga.gov.au\/resources\/auspmd\/covid-19-vaccine-astrazeneca#:\u223c:text=COVID-19%20Vaccine%20AstraZeneca%20%28ChAdOx1-S%29%20was%20approved%20for%20the,of%20coronavirus%20disease%202019%20%28COVID-19%29%20caused%20by%20SARS-CoV-2."},{"key":"10.1016\/j.vaccine.2024.01.045_b0035","unstructured":"Government of Canada. Vaxzevria (ChAdOx1-S [recombinant]). 2021. Last accessed 27 November 2023; Available from: https:\/\/covid-vaccine.canada.ca\/vaxzevria\/product-details."},{"key":"10.1016\/j.vaccine.2024.01.045_b0040","doi-asserted-by":"crossref","unstructured":"Lythgoe MP, Middleton P. Comparison of COVID-19 vaccine approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. JAMA Network Open. 2021;4:e2114531-e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.14531.","DOI":"10.1001\/jamanetworkopen.2021.14531"},{"key":"10.1016\/j.vaccine.2024.01.045_b0045","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0050","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0055","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0060","unstructured":"Paul Ehrlich Institut. The Paul Ehrlich Institut informs - temporary suspension of vaaccination with COVID-19 Vaccine AstraZeneca. 2021. Last accessed 27 November 2023; Available from: https:\/\/www.pei.de\/EN\/newsroom\/hp-news\/2021\/210315-pei-informs-temporary-suspension-vaccination-astra-zeneca.html."},{"key":"10.1016\/j.vaccine.2024.01.045_b0065","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). 2021. Last accessed 27 November 2023; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-6-9-april-2021_en.pdf."},{"key":"10.1016\/j.vaccine.2024.01.045_b0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5694\/mja2.51135","article-title":"The first known case of vaccine-induced thrombotic thrombocytopenia in Australia","volume":"215","author":"Hocking","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2024.01.045_b0075","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.7861\/clinmed.2021-0488","article-title":"VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme","volume":"21","author":"Chevassut","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.vaccine.2024.01.045_b0080","doi-asserted-by":"crossref","unstructured":"See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325:2448-56. https:\/\/doi.org\/10.1001\/jama.2021.7517.","DOI":"10.1001\/jama.2021.7517"},{"key":"10.1016\/j.vaccine.2024.01.045_b0085","series-title":"Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19): interim guidance, 19 July 2021","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.vaccine.2024.01.045_b0090","unstructured":"Brighton Collaboration. Updated interim case definition of thrombosis with thrombocytopenia syndrome (TTS). 2021. Last accessed 27 November 2021; Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2023\/08\/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdf."},{"key":"10.1016\/j.vaccine.2024.01.045_b0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15585\/mmwr.mm7103a4","article-title":"Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the Advisory Committee on Immunization Practices - United States, December 2021","volume":"71","author":"Oliver","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.01.045_b0100","unstructured":"World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). 2023. Last accessed 25 October 2023; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240061989."},{"key":"10.1016\/j.vaccine.2024.01.045_b0105","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMc2307721","article-title":"Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies","volume":"389","author":"Warkentin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0110","author":"SPEAC: Safety Platform for Emergency Vaccines,"},{"key":"10.1016\/j.vaccine.2024.01.045_b0115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022136","article-title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure","author":"Sch\u00f6nborn","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.01.045_b0120","unstructured":"Shimabukuro T. Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. 2021. Last accessed 23 October 2023; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-05-12\/07-COVID-Shimabukuro-508.pdf."},{"key":"10.1016\/j.vaccine.2024.01.045_b0125","article-title":"Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance","volume":"375","author":"Pavord","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.045_b0130","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2007.02.067","article-title":"Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Wise","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.045_b0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2141.2011.08981.x","article-title":"Influence of age, sex and ethnicity on platelet count in five Italian geographic isolates: mild thrombocytopenia may be physiological","volume":"157","author":"Biino","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0140","article-title":"Thrombosis with thrombocytopenia syndrome following adenovirus vector-based vaccines to prevent COVID-19: epidemiology and clinical presentation in Spain","author":"Garc\u00eda-Azor\u00edn","year":"2022","journal-title":"Neurologia"},{"key":"10.1016\/j.vaccine.2024.01.045_b0145","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1016\/j.vaccine.2022.09.001","article-title":"Thrombosis and thromboembolism: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Gollamudi","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.045_b0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ejh.13917","article-title":"Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review","volume":"110","author":"Bidari","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0155","doi-asserted-by":"crossref","unstructured":"Thiele T, Esfeld M, Handtke S, Rath J, Sch\u00f6nborn L, Antovich J, et al. PB1338 - Thrombotic thrombocytopenia syndrome after vaccination against COVID-19 associated with antiplatelet antibodies. Montreal, Canada2023. Last accessed 24 October 2023; Available from: https:\/\/isth2023.eventscribe.net\/searchGlobal.asp.","DOI":"10.1016\/j.rpth.2023.101447"},{"key":"10.1016\/j.vaccine.2024.01.045_b0160","article-title":"COVID-19 vaccines and autoimmune hematologic disorders","volume":"10","author":"Mingot-Castellano","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.045_b0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2022.04.020","article-title":"Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases","volume":"214","author":"Saluja","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.vaccine.2024.01.045_b0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.seminhematol.2022.02.002","article-title":"Epidemiology of VITT","volume":"59","author":"Pai","year":"2022","journal-title":"Semin Hematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0175","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2210813","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine","volume":"387","author":"Herrera-Comoglio","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0180","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.7326\/L21-0244","article-title":"Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine","volume":"174","author":"Sangli","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0185","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/M22-0118","article-title":"The epidemiology of thrombosis with thrombocytopenia syndrome: analogies with heparin-induced thrombocytopenia","volume":"175","author":"Warkentin","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0200","unstructured":"Oliver S. Updates to the benefit\/risk assessment for Janssen COVID-19 vaccines: Applying the Evidence to Recommendation Framework. 2021. Last accessed 24 October 2023; Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-12-16\/04_covid_oliver_2021-12-16.pdf."},{"key":"10.1016\/j.vaccine.2024.01.045_b0205","unstructured":"Medicines & Healthcare products Regulatory Agency. Coronavirus vaccines: Summary of Yellow Card reporting. 2022. Last accessed 6 September 2023; Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1128782\/Coronavirus_Vaccine_-_Summary_of_Yellow_Card_reporting_23.11.2022_final.pdf."},{"key":"10.1016\/j.vaccine.2024.01.045_b0210","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.vaccine.2023.03.071","article-title":"Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem","volume":"41","author":"Clarke","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.045_b0215","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0220","article-title":"Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England","volume":"13","author":"Andrews","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2024.01.045_b0225","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019 update. 2021. Last accessed 24 October 2023; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241516990."},{"key":"10.1016\/j.vaccine.2024.01.045_b0230","first-page":"e73","volume":"9","author":"Klok","year":"2022","journal-title":"Vaccine-induced immune thrombotic thrombocytopenia Lancet Haematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2022.02.004","article-title":"Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"59","author":"Greinacher","year":"2022","journal-title":"Semin Hematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0240","unstructured":"European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 2022. Last accessed 25 Ocotber 2023; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria."},{"key":"10.1016\/j.vaccine.2024.01.045_b0245","article-title":"Fact sheet for healthcare providers administering vaccine (vaccination providers) 2023","volume":"25","author":"Food and Drug Administration","year":"2023","journal-title":"Last accessed"},{"key":"10.1016\/j.vaccine.2024.01.045_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Sharifian-Dorche","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2024.01.045_b0255","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","volume":"385","author":"Salih","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0260","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/imj.15783","article-title":"Understanding vaccine-induced thrombotic thrombocytopenia (VITT)","volume":"52","author":"Dix","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.vaccine.2024.01.045_b0265","article-title":"Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family","author":"Noy\u00e9","year":"20222056","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.vaccine.2024.01.045_b0270","article-title":"Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway","author":"Salih","year":"20222036","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.vaccine.2024.01.045_b0275","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.01.045_b0280","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.01.045_b0285","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2021.280154","article-title":"Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines","volume":"107","author":"Michalik","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2024.01.045_b0290","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","author":"Baker","year":"202178213","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.01.045_b0295","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJMc2310644","article-title":"More on adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies","volume":"389","author":"Campello","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0300","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284127","article-title":"Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection","author":"Uzun","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2024.01.045_b0305","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.2021014712","article-title":"Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration","volume":"140","author":"Nicolai","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.01.045_b0310","article-title":"Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review","author":"Warkentin","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0315","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0320","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.jtha.2023.04.034","volume":"21","author":"Warkentin","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0325","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1055\/a-1535-9002","article-title":"PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison","volume":"121","author":"Sachs","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0330","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients","volume":"20","author":"Favaloro","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0335","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1309\/AJCPG0MNR5NGKNFX","article-title":"Platelet factor 4\/heparin antibodies in blood bank donors","volume":"134","author":"Hursting","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0340","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2011-03-342857","article-title":"Association of natural anti-platelet factor 4\/heparin antibodies with periodontal disease","volume":"118","author":"Greinacher","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.01.045_b0345","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2021012217","article-title":"Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"138","author":"Thiele","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.01.045_b0350","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/jth.15352","article-title":"An observational study to identify the prevalence of thrombocytopenia and anti-PF4\/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination","volume":"19","author":"S\u00f8rvoll","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0355","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/ijlh.13774","article-title":"Low clinical utility of testing for anti-platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoV-19 vaccine","volume":"44","author":"Barefah","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12959-023-00533-z","article-title":"Incidence of anti-platelet factor4\/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais","volume":"21","author":"Boonyawat","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.vaccine.2024.01.045_b0365","doi-asserted-by":"crossref","first-page":"e12580","DOI":"10.1002\/rth2.12580","article-title":"Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination","volume":"5","author":"Uaprasert","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0370","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 Immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.045_b0375","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1111\/jth.15862","article-title":"Quantitative interpretation of PF4\/heparin-EIA optical densities in predicting platelet-activating VITT antibodies","volume":"20","author":"Sch\u00f6nborn","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0380","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/bloodadvances.2021006698","article-title":"A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Lee","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2024.01.045_b0385","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2022007766","article-title":"The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Bissola","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2024.01.045_b0390","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.26488","article-title":"Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies","volume":"97","author":"Kanack","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vaccine.2024.01.045_b0395","doi-asserted-by":"crossref","unstructured":"Chen VM, Curnow JL, Tran HA, Choi PY. Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. Med J Aust. 2021;215:245-9.e1. https:\/\/doi.org\/10.5694\/mja2.51229.","DOI":"10.5694\/mja2.51229"},{"key":"10.1016\/j.vaccine.2024.01.045_b0400","article-title":"The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study","volume":"40","author":"Tran","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2024.01.045_b0405","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1055\/a-1681-7286","article-title":"Vaccine-induced thrombotic thrombocytopenia: insights from blood smear","volume":"121","author":"Zimmermann","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.01.045_b0410","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.vaccine.2008.11.036","article-title":"Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies","volume":"27","author":"Bonhoeffer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.045_b0415","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.vaccine.2008.11.035","article-title":"Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems","volume":"27","author":"Bonhoeffer","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:07Z","timestamp":1759404787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0264410X24000574"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}